Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $8.50 in the prior trading day, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $8.49, down -0.12%. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 2.75 million shares were traded. ARQT stock price reached its highest trading level at $8.58 during the session, while it also had its lowest trading level at $8.18.
Ratios:
Our goal is to gain a better understanding of ARQT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.19 and its Current Ratio is at 8.46. In the meantime, Its Debt-to-Equity ratio is 1.11 whereas as Long-Term Debt/Eq ratio is at 1.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 03, 2024, Upgraded its rating to Buy and sets its target price to $8 from $4 previously.
On October 26, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $57 to $4.
Goldman Downgraded its Buy to Neutral on October 13, 2023, whereas the target price for the stock was revised from $32 to $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 02 ’24 when Matsuda Masaru sold 5,220 shares for $9.02 per share. The transaction valued at 47,064 led to the insider holds 183,288 shares of the business.
Burnett Patrick sold 13,206 shares of ARQT for $119,106 on Aug 02 ’24. The insider now owns 196,587 shares after completing the transaction at $9.02 per share. On Aug 02 ’24, another insider, Watanabe Todd Franklin, who serves as the insider of the company, sold 14,487 shares for $9.02 each. As a result, the insider received 130,648 and left with 846,263 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 992404544 and an Enterprise Value of 837530816. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.51 while its Price-to-Book (P/B) ratio in mrq is 5.30. Its current Enterprise Value per Revenue stands at 6.342 whereas that against EBITDA is -4.698.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $13.17, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is -9.00%, while the 200-Day Moving Average is calculated to be 17.41%.
Shares Statistics:
The stock has traded on average 2.70M shares per day over the past 3-months and 2701240 shares per day over the last 10 days, according to various share statistics. A total of 116.89M shares are outstanding, with a floating share count of 101.14M. Insiders hold about 13.42% of the company’s shares, while institutions hold 99.65% stake in the company. Shares short for ARQT as of 1722384000 were 21951160 with a Short Ratio of 8.14, compared to 1719532800 on 21340671. Therefore, it implies a Short% of Shares Outstanding of 21951160 and a Short% of Float of 23.52.
